Wall Street analysts expect Advaxis, Inc. (NASDAQ:ADXS) to post earnings of ($1.24) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Advaxis’ earnings. Advaxis posted earnings per share of ($4.05) in the same quarter last year, which suggests a positive year-over-year growth rate of 69.4%. The firm is scheduled to report its next quarterly earnings results on Monday, September 9th.
According to Zacks, analysts expect that Advaxis will report full year earnings of ($2.70) per share for the current year. For the next financial year, analysts expect that the firm will report earnings of ($2.41) per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Advaxis.
A number of equities research analysts have recently issued reports on ADXS shares. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. HC Wainwright reaffirmed a “neutral” rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th. Finally, Zacks Investment Research raised shares of Flagstar Bancorp from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a report on Monday, July 8th.
Institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its holdings in shares of Advaxis by 5,970.3% in the fourth quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after buying an additional 553,031 shares during the last quarter. Two Sigma Investments LP raised its holdings in shares of Advaxis by 2,468.2% in the fourth quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after buying an additional 355,415 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Advaxis by 3.1% in the fourth quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after buying an additional 43,368 shares during the last quarter. 24.40% of the stock is owned by institutional investors and hedge funds.
Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.
Further Reading: The primary rules of Elliott Wave theory
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.